Genetic Testing and Management Tool

Factor V Leiden (FVL) is the most common genetic risk factor for venous thromboembolism (VTE) and occurs in about 5% of the Caucasian population.  It is considered to be a moderate risk factor for VTE, and its clinical expression is influenced by co-existing genetic factors, in addition to acquired and circumstantial risk factors.  FVL status seems to have little or no effect on recurrence risk of VTE, does not influence treatment following a VTE event, and is not an indication for primary prophylactic treatment in asymptomatic carriers.  There is consensus that in some circumstances genetic testing for FVL has utility, as carriers should be educated about circumstances that might increase the likelihood of VTE, signs and symptoms of VTE, and the potential need for prophylactic anticoagulation in high-risk circumstances.

For more details see the GEC-KO on the run for a concise summary, or the GEC-KO Messenger for a more comprehensive  summary.

The following tool contains:

• When to offer genetic testing for factor V Leiden (FVL)
• Management recommendations for asymptomatic FVL carriers

  Factor V Leiden point of care tool

–

GEC-KO aims to aid the practicing non-genetics health professional by providing informed opinions regarding genetic/genomic conditions, services and technologies that have been developed in a rigorous and evidence-based manner with periodic updating.  The content on the GEC-KO site is for educational purposes only.  No resource should be used as a substitute for clinical judgement.  GEC-KO assumes no responsibility or liability resulting from the use of information contained herein.